ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
de Boer
Rudolf A
RA
van Veldhuisen
Dirk J
DJ
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000627:therapeutic use*; D054143:Heart Failure, Systolic / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood; D011412:Propanolamines / Q000627:therapeutic use*; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D002227:Carbazoles; D010446:Peptide Fragments; D011412:Propanolamines; C109794:pro-brain natriuretic peptide (1-76); D000077261:Carvedilol; D020097:Natriuretic Peptide, Brain; D004656:Enalapril